HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target.
Syros Pharmaceuticals Q4 EPS $(0.17) Beats $(1.35) Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(1.35) by 87.41 percent. This is a 95.53 percent increase over losses of $(3.80) per share
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Piper Sandler Maintains Overweight on Syros Pharmaceuticals, Lowers Price Target to $20
Piper Sandler analyst Edward Tenthoff maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and lowers the price target from $27 to $20.
HC Wainwright & Co. Maintains Buy on Syros Pharmaceuticals, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew Fein maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and raises the price target from $6 to $20.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Syros Pharmaceuticals To Present Initial Data From SELECT-AML-1 Phase 2 Trial At 64th ASH Annual Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing
Looking Into Syros Pharmaceuticals’s Recent Short Interest
Syros Pharmaceuticals's (NASDAQ:SYRS) short percent of float has fallen 48.18% since its last report. The company recently reported that it has 775 thousand shares sold short, which is 4.12% of all regular shares that are available for trading.